← Return to the complete list of publications

Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.

Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J

Purple Squirrel Economics, New York, NY, USA.

Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists.

Appl Health Econ Health Policy 2019;17(6):827-839.

Pubmed ID: 31392669

Follow IRIC

Logo UdeM